Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 2/20 | 1.00 |
| ▸ | KIF20A | O95235 | 12/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 7/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18301135 | 1.00 | PIP4K2A (1.00) | PIP4K2AKIF20ADYRK1AMEN1NPC1 | |
| SCHEMBL18311452 | 0.90 | PIP4K2A (0.82) | PIP4K2AKIF20ADYRK1AMEN1NPC1 | |
| SCHEMBL21578427 | 0.89 | PIP4K2A (0.79) | PIP4K2AKIF20ADYRK1AMEN1NPC1 | |
| SCHEMBL20293903 | 0.87 | PIP4K2A (0.77) | PIP4K2AKIF20ADYRK1AMEN1NPC1 | |
| SCHEMBL18301130 | 0.86 | PIP4K2A (0.76) | PIP4K2AKIF20ADYRK1AMEN1KMT2A | |
| SCHEMBL18301129 | 0.86 | PIP4K2A (0.76) | PIP4K2AKIF20ADYRK1AMEN1KMT2A | |
| SCHEMBL20293907 | 0.86 | PIP4K2A (0.76) | PIP4K2AKIF20ADYRK1ACLK1CLK2 | |
| SCHEMBL18301139 | 0.86 | PIP4K2A (0.76) | PIP4K2AKIF20ADYRK1AMEN1KMT2A | |
| SCHEMBL18301105 | 0.86 | PIP4K2A (0.76) | PIP4K2AKIF20ADYRK1ACLK1CLK2 | |
| SCHEMBL18301140 | 0.86 | PIP4K2A (0.76) | PIP4K2AKIF20ADYRK1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | claimed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | claimed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | claimed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-20190350964-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | NAT UNIV SINGAPORE (SG) | 2019-11-21 | — | — | US | disclosed |
| US-20190350964-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | NAT UNIV SINGAPORE (SG) | 2019-11-21 | — | — | US | disclosed |
| EP-3551184-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | National University of Singapore (SG) | 2019-10-16 | — | — | EP | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| WO-2018106192-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307724-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | National University of Singapore (SG) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016200339-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016200339-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308631-B2 | Selective anti-cancer compounds | CCNA1, CCNY, CCNT1 | PIP4K2A 2352/4885KIF20A 3183/4885DYRK1A 1879/4885 |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | CCNA1, CCNY, CCNT1 | PIP4K2A 2352/4885KIF20A 3183/4885DYRK1A 1879/4885 |
| US-20190350964-A1 | ANTI-CANCER COMPOUNDS AND USES THEREOF | PIK3CD, PIK3CA, PI4KB | PIP4K2A 22/4885KIF20A 2768/4885DYRK1A 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.